share_log

BRIEF-Syndax Announces Orphan Drug Designation Granted To Axatilimab

路透社 ·  Mar 31, 2021 19:49
March 31 (Reuters) - Syndax Pharmaceuticals Inc :
   * SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment